Insulin Lispro vs Insulin Aspart (Ultra-Rapid)
Insulin lispro (Humalog) and insulin aspart (NovoRapid/NovoLog) are both rapid-acting insulin analogs designed to accelerate absorption from subcutaneous injection sites. They achieve ultra-rapid pharmacokinetics through distinct structural modifications: lispro inverts Pro-Lys at positions B28-B29 to Lys-Pro, while aspart substitutes AsnB28 with Pro. Both modifications reduce insulin self-association, producing faster absorption and shorter duration of action compared to regular human insulin.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Insulin Lispro
Section titled “Insulin Lispro”Insulin lispro is a recombinant human insulin analog with a single structural modification: inversion of the B28-B29 sequence from Pro-Lys (native) to Lys-Pro. This modification disrupts the di-hexamer interface that normally stabilizes insulin in solution, reducing self-association and accelerating dissociation into active monomers after subcutaneous injection.
The structural rationale:
- Native insulin: ProB28-LysB29 forms a type II β-turn that stabilizes the di-hexamer
- Lispro: LysB28-ProB29 disrupts this turn, destabilizing hexameric assembly
- Result: Faster hexamer dissociation → faster monomer absorption → faster onset
Insulin Aspart
Section titled “Insulin Aspart”Insulin aspart substitutes AsnB28 with Pro (AsnB28→Pro), directly disrupting the di-hexamer interface. This modification similarly destabilizes hexameric insulin, accelerating absorption. The mechanism is analogous to lispro but involves a different residue position.
The structural rationale:
- Native insulin: AsnB28 is critical for hexamer stabilization via hydrogen bonding
- Aspart: ProB28 cannot form hydrogen bonds, destabilizing the hexamer
- Result: Faster hexamer dissociation → faster monomer absorption → faster onset
Comparison Table
Section titled “Comparison Table”| Property | Insulin Lispro (Humalog) | Insulin Aspart (NovoRapid) |
|---|---|---|
| B28 modification | Lys (native → LysB28) | Pro (AsnB28→Pro) |
| B29 modification | Pro (native → ProB29) | Lys (native) |
| Amino acid changes | Sequence inversion (B28-29) | Single substitution (B28) |
| Self-association | Reduced di-hexamer | Reduced di-hexamer |
| Onset of action | 10–15 minutes | 10–15 minutes |
| Peak effect | 30–90 minutes | 30–90 minutes |
| Duration | 3–5 hours | 3–5 hours |
| Bioavailability | ~60–80% | ~60–80% |
| Brand names | Humalog, Admelog, Lyumjev | NovoRapid, NovoLog, Fiasp |
| Formulation | Clear solution | Clear solution |
| Preservative | Metacresol, phenol | Metacresol, phenol |
| pH | 7.0–8.5 | 7.0–8.5 |
Ultra-Rapid Formulations
Section titled “Ultra-Rapid Formulations”Lispro Ultra-Rapid (Lyumjev)
Section titled “Lispro Ultra-Rapid (Lyumjev)”Lyumjev is an ultra-rapid formulation of insulin lispro containing:
- Insulin lispro: Standard rapid-acting analog
- Tregopil (niacinamide derivative): Accelerates absorption via vasodilation
- Citrate: Further enhances local vasodilation
- Result: Faster onset (5–10 minutes) and earlier peak (30–60 minutes) compared to standard lispro
Lyumjev achieves approximately 30% faster onset compared to standard Humalog, with the earlier peak providing better postprandial glucose control.
Aspart Ultra-Rapid (Fiasp)
Section titled “Aspart Ultra-Rapid (Fiasp)”Fiasp is an ultra-rapid formulation of insulin aspart containing:
- Insulin aspart: Standard rapid-acting analog
- Niacinamide (vitamin B3): Enhances absorption rate via vasodilation
- L-arginine: Stabilizes formulation
- Result: 50% faster early exposure (0–120 min AUC) compared to standard NovoRapid
Fiasp achieves approximately 50% faster initial absorption compared to standard NovoRapid, with the earliest glucose-lowering effect detectable within 2.5 minutes of injection.
Pharmacokinetics
Section titled “Pharmacokinetics”Standard Formulations
Section titled “Standard Formulations”| Parameter | Lispro (Humalog) | Aspart (NovoRapid) |
|---|---|---|
| Tmax | 30–90 min | 30–90 min |
| T50% onset | 10–15 min | 10–15 min |
| Peak glucose-lowering | 1–2 hours | 1–2 hours |
| Duration | 3–5 hours | 3–5 hours |
| Bioavailability | 60–80% | 60–80% |
Ultra-Rapid Formulations
Section titled “Ultra-Rapid Formulations”| Parameter | Lispro (Lyumjev) | Aspart (Fiasp) |
|---|---|---|
| Tmax | 20–60 min | 20–60 min |
| T50% onset | 5–10 min | 5–10 min |
| Peak glucose-lowering | 1–1.5 hours | 1–1.5 hours |
| Duration | 3–5 hours | 3–5 hours |
| Early exposure (0–120 min) | ~50% faster than standard | ~50% faster than standard |
Postprandial Glucose Control
Section titled “Postprandial Glucose Control”Standard Rapid-Acting Analogs
Section titled “Standard Rapid-Acting Analogs”Both lispro and aspart provide comparable postprandial glucose control when dosed at meal start:
| Time Post-Meal | Lispro Glucose Excursion | Aspart Glucose Excursion |
|---|---|---|
| 0–30 min | Rising | Rising |
| 30–60 min | Peak (180–220 mg/dL) | Peak (180–220 mg/dL) |
| 1–2 hours | Declining | Declining |
| 2–3 hours | Near baseline | Near baseline |
| 3–4 hours | Baseline | Baseline |
Ultra-Rapid Formulations
Section titled “Ultra-Rapid Formulations”Ultra-rapid formulations (Lyumjev, Fiasp) can be dosed at meal start or within 15–20 minutes after starting a meal, providing:
- Faster onset: Earlier glucose-lowering effect reduces early postprandial excursion
- Earlier peak: Better match to rapid carbohydrate absorption
- More flexible dosing: Can dose after starting a meal (not just before)
Clinical Evidence
Section titled “Clinical Evidence”Postprandial Glucose Control
Section titled “Postprandial Glucose Control”| Study | Comparison | Primary Outcome | Result |
|---|---|---|---|
| JAB 2230 (Fiasp vs NovoRapid) | Fiasp vs NovoRapid (MDI) | Postprandial glucose (0–2 hr) | -13 mg/dL (Fiasp) |
| BEGIN BT (Fiasp vs NovoRapid) | Fiasp vs NovoRapid (pump) | HbA1c, postprandial | Non-inferior |
| Lyumjev vs Humalog (PRONTO-T1D) | Lyumjev vs Humalog (MDI) | HbA1c, time in range | TIR +5% (Lyumjev) |
Hypoglycemia
Section titled “Hypoglycemia”| Study | Comparison | Nocturnal Hypoglycemia | Severe Hypoglycemia |
|---|---|---|---|
| JAB 2230 | Fiasp vs NovoRapid | No difference | No difference |
| PRONTO-T1D | Lyumjev vs Humalog | No difference | No difference |
| Meta-analyses | Rapid-acting analogs vs regular | Lower (rapid-acting) | Lower (rapid-acting) |
Both ultra-rapid formulations demonstrate non-inferiority for overall glycemic control with no increase in hypoglycemia risk compared to standard rapid-acting analogs.
Pump Compatibility
Section titled “Pump Compatibility”Standard Rapid-Acting Analogs
Section titled “Standard Rapid-Acting Analogs”Both lispro and aspart are approved for use in insulin pumps:
- Omnipod (insulin lispro): FDA-approved
- MiniMed 670G/770G (insulin aspart): FDA-approved
- Tandem t:slim X2 (both): FDA-approved
- Stability in pump: 24–48 hours (28-day reservoir limit)
Ultra-Rapid Formulations in Pumps
Section titled “Ultra-Rapid Formulations in Pumps”- Lyumjev: FDA-approved for Omnipod 5 and Tandem Control-IQ
- Fiasp: FDA-approved for MiniMed 770G and Omnipod 5
- Earlier peak in pump: Provides faster correction boluses
- Similar total daily dose: No significant difference in total insulin requirements
Mixing and Compatibility
Section titled “Mixing and Compatibility”Both lispro and aspart are compatible with:
- NPH insulin: Can be mixed in the same syringe (inject rapidly after mixing)
- Long-acting analogs: Not mixed (separate injections)
- Glucagon: Not compatible in the same syringe
- Pramlintide: Compatible in pump co-formulations (clinical trials)
Clinical Decision Framework
Section titled “Clinical Decision Framework”Choose insulin lispro when:
- Standard rapid-acting insulin is needed
- Cost is a primary concern (lispro biosimilars are available)
- Pump therapy with lispro is established
- Admelog biosimilar offers cost savings
- Lyumjev (ultra-rapid) is preferred for postprandial control
Choose insulin aspart when:
- Standard rapid-acting insulin is needed
- NovoRapid is the formulary standard
- Fiasp (ultra-rapid) is preferred for postprandial control
- Pump therapy with aspart is established
- NovoLog biosimilar offers cost savings
Choose ultra-rapid (Lyumjev/Fiasp) when:
- Postprandial glucose control is suboptimal with standard rapid-acting
- Flexible dosing (after meal start) is desired
- Insulin pump correction boluses need faster onset
- High glycemic variability requires more responsive insulin
- Cost difference is not prohibitive
References
Section titled “References”- Howey DC, et al. “Insulin lispro: pharmacokinetics and pharmacodynamics.” Diabetes 1994;43:396-402.
- Lindholm A, et al. “Insulin aspart: pharmacokinetics and pharmacodynamics.” Diabet Med 1996;13:758-764.
- Heise T, et al. “Ultra-rapid acting insulin aspart: pharmacokinetics of Fiasp.” Diabetes Obes Metab 2019;21:2074-2082.
- Bergenstal RM, et al. “Lyumjev vs Humalog in type 1 diabetes (PRONTO-T1D).” Diabetes Obes Metab 2020;22:1420-1429.
- Klonoff DC, et al. “Ultra-rapid-acting insulin: clinical evidence and patient selection.” Diabetes Spectr 2021;34:342-349.